Loss of PRP4K drives anoikis resistance in part by dysregulation of epidermal growth factor receptor endosomal trafficking

被引:19
作者
Corkery, D. P. [1 ,2 ]
Clarke, L. E. [2 ]
Gebremeskel, S. [3 ]
Salsman, J. [2 ]
Pinder, J. [2 ]
Le Page, C. [4 ,5 ]
Meunier, L. [4 ,5 ]
Xu, Z. [2 ]
Mes-Masson, A-M [4 ,5 ,6 ]
Berman, J. N. [2 ,3 ,7 ,8 ]
Johnston, B. [2 ,3 ,8 ,9 ]
Dellaire, G. [1 ,2 ,8 ]
机构
[1] Dalhousie Univ, Dept Biochem & Mol Biol, Halifax, NS, Canada
[2] Dalhousie Univ, Dept Pathol, POB 15000, Halifax, NS B3H 4R2, Canada
[3] Dalhousie Univ, Dept Microbiol & Immunol, Halifax, NS, Canada
[4] Ctr Hosp Univ Montreal CRCHUM, Ctr Rech, Montreal, PQ, Canada
[5] Inst Canc Montreal, Montreal, PQ, Canada
[6] Univ Montreal, Dept Med, Montreal, PQ, Canada
[7] IWK Hlth Ctr, Dept Pediat, Halifax, NS, Canada
[8] Beatrice Hunter Canc Res Inst, Halifax, NS, Canada
[9] Dalhousie Univ, Dept Pediat, Halifax, NS, Canada
基金
加拿大健康研究院;
关键词
GYNECOLOGIC-ONCOLOGY-GROUP; EPITHELIAL-MESENCHYMAL TRANSITION; OVARIAN-CANCER; MALIGNANT ASCITES; DOWN-REGULATION; CELL-SURVIVAL; EGF RECEPTOR; SR PROTEINS; SPLICING FACTORS; TYROSINE KINASE;
D O I
10.1038/onc.2017.318
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Anoikis acts as a critical barrier to metastasis by inducing cell death upon cancer cell detachment from the extracellular matrix (ECM), thereby preventing tumor cell dissemination to secondary sites. The induction of anoikis requires the lysosomal-mediated downregulation of epidermal growth factor receptors (EGFRs) leading to termination of pro-survival signaling. In this study, we demonstrate that depletion of pre-mRNA splicing factor 4 kinase (PRP4K; also known as PRPF4B) causes dysregulation of EGFR trafficking and anoikis resistance. We also report a novel cytoplasmic localization of PRP4K at the late endosome, and demonstrate both nuclear and cytoplasmic localization in breast, lung and ovarian cancer tissue. Mechanistically, depletion of PRP4K leads to reduced EGFR degradation following cell detachment from the ECM and correlates with increased TrkB, vimentin and Zeb1 expression. As a result, PRP4K loss promotes sustained growth factor signaling and increased cellular resistance to anoikis in vitro and in a novel zebrafish xenotransplantation model of anoikis sensitivity, as well as increased metastasis in a mouse model of ovarian cancer. Thus, PRP4K may serve as a potential biomarker of anoikis sensitivity in ovarian and other epithelial cancers.
引用
收藏
页码:174 / 184
页数:11
相关论文
共 65 条
[1]   Malignant ascites: Past, present, and future [J].
Adam, RA ;
Adam, YG .
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2004, 198 (06) :999-1011
[2]   Getting to know ovarian cancer ascites: opportunities for targeted therapy-based translational research [J].
Ahmed, Nuzhat ;
Stenvers, Kaye L. .
FRONTIERS IN ONCOLOGY, 2013, 3
[3]   Integrin endosomal signalling suppresses anoikis [J].
Alanko, Jonna ;
Mai, Anja ;
Jacquemet, Guillaume ;
Schauer, Kristine ;
Kaukonen, Riina ;
Saari, Markku ;
Goud, Bruno ;
Ivaska, Johanna .
NATURE CELL BIOLOGY, 2015, 17 (11) :1412-1421
[4]   Pattern and prognostic factors in patients with malignant ascites: a retrospective study [J].
Ayantunde, A. A. ;
Parsons, S. L. .
ANNALS OF ONCOLOGY, 2007, 18 (05) :945-949
[5]   Three Common Polymorphisms in the CYBA Gene Form a Haplotype Associated With Decreased ROS Generation [J].
Bedard, Karen ;
Attar, Homa ;
Bonnefont, Jerome ;
Jaquet, Vincent ;
Borel, Christelle ;
Plastre, Olivier ;
Stasia, Marie-Jose ;
Antonarakis, Stylianos E. ;
Krause, Karl-Heinz .
HUMAN MUTATION, 2009, 30 (07) :1123-1133
[6]   Integrated genomic analyses of ovarian carcinoma [J].
Bell, D. ;
Berchuck, A. ;
Birrer, M. ;
Chien, J. ;
Cramer, D. W. ;
Dao, F. ;
Dhir, R. ;
DiSaia, P. ;
Gabra, H. ;
Glenn, P. ;
Godwin, A. K. ;
Gross, J. ;
Hartmann, L. ;
Huang, M. ;
Huntsman, D. G. ;
Iacocca, M. ;
Imielinski, M. ;
Kalloger, S. ;
Karlan, B. Y. ;
Levine, D. A. ;
Mills, G. B. ;
Morrison, C. ;
Mutch, D. ;
Olvera, N. ;
Orsulic, S. ;
Park, K. ;
Petrelli, N. ;
Rabeno, B. ;
Rader, J. S. ;
Sikic, B. I. ;
Smith-McCune, K. ;
Sood, A. K. ;
Bowtell, D. ;
Penny, R. ;
Testa, J. R. ;
Chang, K. ;
Dinh, H. H. ;
Drummond, J. A. ;
Fowler, G. ;
Gunaratne, P. ;
Hawes, A. C. ;
Kovar, C. L. ;
Lewis, L. R. ;
Morgan, M. B. ;
Newsham, I. F. ;
Santibanez, J. ;
Reid, J. G. ;
Trevino, L. R. ;
Wu, Y. -Q. ;
Wang, M. .
NATURE, 2011, 474 (7353) :609-615
[7]   Carboplatin and paclitaxel in ovarian carcinoma: A phase I study of the Gynecologic Oncology Group [J].
Bookman, MA ;
McGuire, WP ;
Kilpatrick, D ;
Keenan, E ;
Hogan, WM ;
Johnson, SW ;
ODwyer, P ;
Rowinsky, E ;
Gallion, HH ;
Ozols, RF .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (06) :1895-1902
[8]   Anoikis resistance is a critical feature of highly aggressive ovarian cancer cells [J].
Cai, Q. ;
Yan, L. ;
Xu, Y. .
ONCOGENE, 2015, 34 (25) :3315-3324
[9]   The Rab5 effector EEA1 is a core component of endosome docking [J].
Christoforidis, S ;
McBride, HM ;
Burgoyne, RD ;
Zerial, M .
NATURE, 1999, 397 (6720) :621-625
[10]   Multiplex Genome Engineering Using CRISPR/Cas Systems [J].
Cong, Le ;
Ran, F. Ann ;
Cox, David ;
Lin, Shuailiang ;
Barretto, Robert ;
Habib, Naomi ;
Hsu, Patrick D. ;
Wu, Xuebing ;
Jiang, Wenyan ;
Marraffini, Luciano A. ;
Zhang, Feng .
SCIENCE, 2013, 339 (6121) :819-823